Navigation Links
Two Additional Private Payers Provide Coverage for Posterior Tibial Nerve Stimulation Delivered Using the Uroplasty Urgent® PC Neuromodulation System
Date:7/18/2011

MINNEAPOLIS, July 18, 2011 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced that two additional private insurance payers will cover  posterior tibial nerve stimulation (PTNS) using its Urgent PC Neuromodulation System for the treatment of overactive bladder (OAB) and associated symptoms.  Effective August 1, 2011, Health Care Service Corporation (HCSC), covering approximately 13 million lives in Texas, Illinois, New Mexico and Oklahoma, will begin covering and paying for PTNS therapy.  HCSC is the second largest Blue Cross Blue Shield affiliate and the fourth largest private payer in the U.S.   Additionally, effective May 18, 2011, BlueCross BlueShield of Nebraska, covering approximately 668,000 lives, initiated coverage of PTNS treatments.  

"This expanded private payer coverage of PTNS is based on a solid foundation of published clinical data as well as compelling presentations at professional meetings delivered by key opinion leaders in urology and urogynecology who have hands on experience with Urgent PC.  The additional coverage is another step forward for our Company as we seek to further expand the adoption of PTNS treatments," said David Kaysen, President and CEO of Uroplasty, Inc. "We have now secured coverage from three of the four largest private payers in the U.S. We estimate that in total the Medicare and private-pay carriers that today provide coverage for PTNS treatments represent approximately 115 million lives. We remain focused on our efforts to garner additional coverage and drive adoption of Urgent PC, and we are optimistic about the potential for our success."

About Uroplasty, Inc.Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions.  Our focus is the continued commercialization of our Urgent PC Neuromodulation System, the only FDA-cleared system that delivers posterior tibial nerve stimulation for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence.  We also offer Macroplastique® Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency.  For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.

Forward-Looking InformationThis press release contains forward-looking statements that reflect our best estimates regarding future events and financial performance.  These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our anticipated results.  We discuss in detail the factors that may affect the achievement of our forward-looking statements in our Annual Report on Form 10-K filed with the SEC.  In particular, we cannot be certain that the rate of reimbursement for PTNS treatments will be adequate to justify the cost of our product, that other Medicare carriers or private payers will provide coverage for this treatment, or that any of the other risks identified in our 10-K will not adversely affect our expectations as described in these forward-looking statements.For Further Information:
Uroplasty, Inc.
David Kaysen, President and CEO, or
Medi Jiwani, Vice President, CFO, Treasurer
952.426.6140 EVC Group
Doug Sherk/Jenifer Kirtland (Investors), 415.896.6820
Chris Gale (Media), 646.201.5431
'/>"/>

SOURCE Uroplasty, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
2. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
3. First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
4. PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy
5. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
6. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
7. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
8. Pharmacopeia Announces Additional Positive Findings from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
9. Sulodexide Data Safety Monitoring Committee Completes Additional Review of Phase 3 Study Data
10. Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R)
11. Paul Capital Healthcare Purchases Additional Royalty Interest in GlaxoSmithKlines Rotarix(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... , Feb. 11, 2016 ... Diagnostics in Personalized Medicine and Cancer Therapy. - ... High-Growth Diagnostic Testing Markets. - Key Diagnostic Testing ... - Molecular Diagnostics in Genetic Testing. - Molecular ... Markets. - Over-the-Counter Diagnostic Products World Markets. ...
(Date:2/11/2016)... Calif., Feb. 11, 2016 PRO-DEX, INC. (NasdaqCM: PDEX) ... ended December 31, 2015. The Company also filed its Quarterly ... year 2016 with the Securities and Exchange Commission today. ... 31, 2015 --> --> ... increased $2.6 million, or 95%, to $5.4 million from $2.8 ...
(Date:2/11/2016)... has committed to provide drug disposal kiosks in ... as part of a program to combat drug ... organization As You Sow. Conrad MacKerron , Senior ... to unneeded drugs because they lack easily accessible collection and ... Conrad MacKerron , Senior Vice President at As You ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... , ... As a former television executive, owner Tal Rabinowitz knows how stressful ... decompress, Rabinowitz found herself drawn to a casual meditation class while working at NBC ... implementing a 20-minute-per-day meditation practice with her team. After her tenure at NBC, she ...
(Date:2/12/2016)... , ... February 12, 2016 , ... ... Leadership Series at Zuckerberg San Francisco General Hospital on April 5-7. The series ... behaviors and create new habits. The workshops cover a broad range of topics, ...
(Date:2/12/2016)... ... 12, 2016 , ... Fisher House Foundation Chairman and CEO Kenneth Fisher joined ... Support Alliance president Scott Bensing, and Peggy Kearns Director, VA Southern Nevada Healthcare System ... This will be the first Fisher House in Nevada, and will provide free ...
(Date:2/12/2016)... , ... February 12, 2016 , ... Vail knee specialist ... Physician Leaders to Know in 2016 . The list consists of physicians establishing, leading ... to establish this list. , An Ambulatory Surgery Center, also known as an ...
(Date:2/12/2016)... San Ramon, CA (PRWEB) , ... February 12, 2016 , ... ... tissue donation in northern California and Nevada, announced a partnership with San Ramon Regional ... be transferred to the hospital’s facilities as a way to accommodate a more certain ...
Breaking Medicine News(10 mins):